CD4 and melanoma: In patients with bladder cancer, breast cancer, non-small cell lung cancer (NSCLC), and melanoma treated with anti-CTLA-4 immunotherapy, increased levels of ICOS+CD4+ T cells in tumor tissue and peripheral blood were detected [9–12].